Latest Pyrazines Stories
NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S.
A typical dose of the medication Pyrazinamide, key to treating tuberculosis, may be too low because of modern-day physiques, U.S. researchers said. Lead author Dr.
The typical dose of a medication considered pivotal in treating tuberculosis effectively is much too low to account for modern-day physiques, UT Southwestern Medical Center researchers said.
The FDA is tightening up on smoking cessation drugs, Chantix and Zyban, by requiring the drugs to be labeled with safety warnings over side effects including depression and suicidal thoughts.
Carfilzomib Achieves 26 Percent Clinical Benefit Response Rate in Phase 2 Trial of Relapsed and Refractory Multiple Myeloma Patients - Proteolix Expands Trial ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- Proteolix, Inc.
Promising Anti-cancer Activity Observed in Relapsed Patients ORLANDO, Fla., and SOUTH SAN FRANCISCO, Calif. , May 30 /PRNewswire/ -- Proteolix, Inc.
Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc.
People with a likely history of depression who take varenicline (ChantixÂ®) do not report more severe mood symptoms, medication side effects, or less success quitting smoking compared to people with no history of depression taking this drug.
New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
EUSAPharma (formerly Cytogen) Posts Positive Phase I Report from Trial of Quadramet in Combination with Velcade for the Treatment of Relapsed or Refractory Multiple Myeloma. LOS ANGELES, Feb.
- An imitative word; an onomatopoetic word.